HIV

A proposed mechanism underlying observed sex differences in HIV-associated vascular risk is increased immune activation in women.

A history of incarceration and homelessness could indicate an increased mortality risk among patients with HIV.

Social and public health providers linking patients to HIV services was found to increase retention in care.

Emergency departments may provide an opportunity to capture those with undiagnosed HIV infection missed by screening programs.

Women with a prior chlamydia infection could have twice the risk of ovarian cancer.

Ibalizumab-uiyk was the first monoclonal antibody approved to treat HIV.

This article highlights several key therapeutics areas with ibalizumab-uiyk that every pharmacist should know.

None of the participants experienced grade 3 or 4 side effects.

A continuing concern is HIV-associated neurologic syndromes.

The median time to viral suppression decreased from 63 days to 45 days post-rapid entry program.

Top news of the day from across the health care landscape.

Top news of the day from across the health care landscape.

HIV is a wide-reaching public health problem, with more than 37 million individuals infected worldwide. Current antiretroviral therapy has a varying array of uses, ranging from HIV treatment to pre-exposure prophylaxis.

There was no statistically significant difference in medication possession ratio among HIV-positive patients taking generic or branded antiretrovirals.

Eliminating dormant HIV reserves that hide from antiretroviral therapy is key to curing the virus.

Findings suggest that incomplete transcription causes latency in HIV infected cells.

Many patients with HIV develop neurocognitive disorders, which is incurable.

Up to half of people living with HIV experience HIV-associated neurocognitive disorders, a neurological manifestation of HIV-1 infection.

A combination therapy that attacks the viral reservoir may be crucial to controlling HIV replication without medication.

New research may overcome hurdles to eliminating viral reservoirs that prevent curing HIV.

The aging HIV population presents challenges to health care providers.

Officials with the FDA have approved ibalizumab-uiyk (Trogarzo, TaiMed Biologics), the first antiretroviral medication for adults with HIV who cannot be successfully treated with other therapies.

Mylan will reduce the wholesale acquisition costs of Smyfi Lo and Cimduo, which are both combination therapies for HIV.

HIV packages a key viral protein in exosomes to transport throughout the body.

New study findings suggest that more at-risk individuals should take pre-exposure prophylaxis to prevent HIV.

The authors of the study acknowledged that there is much more to be understood about the factors that affect adolescents and young adults at high risk for contracting or transmitting HIV.

Pre-exposure prophylaxis saves lives by reducing the risk of acquiring HIV, but the need for cost-saving is great.

Value-based contracts may also improve patient outcomes by increasing access to innovative medicines and supporting appropriate use.

The National Comprehensive Cancer Network seeks to address issues related to treating HIV-positive patients with cancer, such as the potential for drug interactions.

Top news of the week from Specialty Pharmacy Times.